Nucleome Therapeutics

📍 Oxford, United Kingdom🗓 Founded 2019👥 58 employees💰 Last funded Aug 2025
Biotechnology🌐 nucleome.com
Website LinkedIn
Nucleome was founded in 2019. The precision of its 3D genomics technology has the potential to improve drug discovery success rates both by discovering genetically-validated medicines, and by more accurately identifying patients who are likely to benefit from treatments. Nucleome’s platform can be applied to multiple disease indications and cell types, with an initial focus on inflammatory conditions. In addition to building its own pipeline, the company is forging external collaborations in target discovery, target validation, and patient stratification. Nucleome was founded by leading experts in gene regulation from the University of Oxford. The Company is backed by a world-class syndicate of investors that includes M Ventures, the strategic corporate venture capital arm of Merck KGaA; Johnson and Johnson Innovation-JJDC, Inc. (“JJDC”), the strategic venture capital arm of Johnson & Johnson; Pfizer Ventures, the venture group of Pfizer; British Patient Capital; and founding investor Oxford Science Enterprises.
1
Total investors
0
Early stage
0
Mid stage
1
Late stage
2019
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Israel
1
Frequently asked questions
Who invested in Nucleome Therapeutics?
Nucleome Therapeutics has 1 investors on record on gritt.io and 1 late-stage investors.
When did Nucleome Therapeutics last raise funding?
The most recent investment in Nucleome Therapeutics recorded on gritt.io was in August 2025.
When was Nucleome Therapeutics founded?
Nucleome Therapeutics was founded in 2019.
What industry is Nucleome Therapeutics in?
Nucleome Therapeutics operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Nucleome Therapeutics based?
Nucleome Therapeutics is headquartered in Oxford, United Kingdom.